Mounjaro, a recently approved medication for type 2 diabetes, has gained significant recognition in the medical community. This groundbreaking drug, classified as a glucagon-like peptide-1 (GLP-1) receptor agonist, works by enhancing the body's natural regulatory mechanism to lower blood sugar levels. Preliminary clinical trials suggest that Mounja

The pharmaceutical landscape experiencing a revolution with the emergence of novel glucagon-like peptide-1 (GLP-1) receptor agonists. These innovative drugs demonstrate immense potential in managing type 2 diabetes and, consistently, are being explored for their therapeutic benefits in other conditions like obesity and cardiovascular disease. Among